In the present work, we show that the glycerophosphodiesterase EDI3 is highly expressed in ER − HER2 + breast cancers, and that downregulating EDI3 in ER − HER2 + cells decreases viability more efficiently compared to those that are ER + HER2 + . This evidence concerns the gene ERBB2 and breast carcinoma.